We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

86 hedge funds and large institutions have $176M invested in Akebia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 27

20% more capital invested

Capital invested by funds: $147M → $176M (+$29.2M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less funds holding

Funds holding: 93 → 86 (-7)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

49% less call options, than puts

Call options by funds: $1.47M | Put options by funds: $2.86M

Holders
86
Holders Change
-7
Holders Change %
-7.53%
% of All Funds
2.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
33
Reduced
27
Closed
15
Calls
$1.47M
Puts
$2.86M
Net Calls
-$1.4M
Net Calls Change
-$46K

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$2.74M
2
GTC
Ghost Tree Capital
New York
+$2.55M
3
NCM
Nantahala Capital Management
Connecticut
+$1.99M
4
Marshall Wace
Marshall Wace
United Kingdom
+$1.36M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.08M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.43M
2
EAM
EverPoint Asset Management
Connecticut
-$1.5M
3
First Manhattan
First Manhattan
New York
-$1.35M
4
TC
TFS Capital
Pennsylvania
-$1.3M
5
LCM
Landscape Capital Management
New Jersey
-$891K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBHC
76
Brown Brothers Harriman & Co
New York
$3K -$17K -2,000 -86%
Barclays
77
Barclays
United Kingdom
$3K -$1.23K -145 -29%
Bank of Montreal
78
Bank of Montreal
Ontario, Canada
$2K – – –
MFS
79
MSI Financial Services
Massachusetts
$2K – – –
AG
80
Advisor Group
Arizona
$2K +$825 +97 +51%
LTFS
81
Ladenburg Thalmann Financial Services
Florida
$1K – – –
WA
82
WFG Advisors
Texas
$1K – – –
TCIM
83
TIAA CREF Investment Management
New York
$989 -$20.2K -2,377 -2%
VOYA Investment Management
84
VOYA Investment Management
Georgia
$150 – – –
EAM
85
EverPoint Asset Management
Connecticut
– -$1.5M -200,000 Closed
TC
86
TFS Capital
Pennsylvania
– -$1.3M -173,312 Closed
PAWC
87
P.A.W. Capital
Connecticut
– -$299K -40,000 Closed
EA
88
Emerald Acquisition
Washington
– -$289K -38,666 Closed
TI
89
Trexquant Investment
Connecticut
– -$243K -32,442 Closed
Citadel Advisors
90
Citadel Advisors
Florida
– -$193K -25,818 Closed
DCM
91
DAFNA Capital Management
California
– -$185K -24,700 Closed
VAM
92
Visium Asset Management
New York
– -$161K -21,526 Closed
DTL
93
Dynamic Technology Lab
Singapore
– -$147K -19,629 Closed
Jacobs Levy Equity Management
94
Jacobs Levy Equity Management
New Jersey
– -$123K -16,465 Closed
Connor, Clark & Lunn Investment Management (CC&L)
95
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$120K -16,100 Closed
ID
96
Integral Derivatives
New York
– -$114K -13,400 Closed
Citigroup
97
Citigroup
New York
– -$68.8K -8,094 -100%
CFA
98
Camarda Financial Advisors
Florida
– -$15K -2,000 Closed
JP Morgan Chase
99
JP Morgan Chase
New York
– -$10K -1,292 Closed
CSS
100
Cubist Systematic Strategies
Connecticut
– -$5K -694 Closed
1 2 3
4
5

AKBA Hedge Fund Activity: Q3 2016 in Review

86 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2016, worth a combined $176M — up 20% from $147M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of AKBA and 8 opened new positions — a net loss of 7 holders — while 27 trimmed existing stakes and 33 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $2.74M. The largest seller was Fidelity Investments, cutting an estimated $6.43M.

  • 86 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2016, down from 93 in Q2 2016.
  • Funds reported $176M of Akebia Therapeutics stock for Q3 2016, up 20% quarter-over-quarter.
  • 8 funds opened new Akebia Therapeutics positions in Q3 2016 and 15 closed out, a net change of -7 holders.
  • The largest Akebia Therapeutics buyer in Q3 2016 was Avoro Capital Advisors, an estimated $2.74M added.
  • The largest Akebia Therapeutics seller in Q3 2016 was Fidelity Investments, an estimated $6.43M sold.

Based on aggregated 13F filings for Q3 2016.